Background and Objectives: High-volume local infiltration analgesia (LIA) is widely applied as part of a multimodal pain management strategy in total hip arthroplasty (THA). However, methodological problems hinder the exact interpretation of previous trials, and the evidence for LIA in THA remains to be clarified. Therefore, we evaluated whether intraoperative high-volume LIA, in addition to a multimodal oral analgesic regimen, would further reduce acute postoperative pain after THA.
Methods: Patients scheduled for unilateral, primary THA under spinal anesthesia were included in this randomized, double-blind, placebocontrolled trial receiving high-volume (150 mL) wound infiltration with ropivacaine 0.2% with epinephrine (10 Kg/mL) or saline 0.9%. A multimodal oral analgesic regimen consisting of slow-release acetaminophen 2 g, celecoxib 400 mg, and gabapentin 600 mg was instituted preoperatively. Rescue analgesic consisted of oral oxycodone. Pain was assessed repeatedly the first 8 hrs after surgery using the 100-mm visual analog scale. The primary end point was pain during walking (5 m) 8 hrs after surgery. Secondary end points were pain at rest, pain on 45 degrees of passive flexion of the hip with the leg straight, and cumulative consumption of oxycodone.
Results: A total of 120 patients were included. Pain during walking Conclusions: Intraoperative high-volume LIA with ropivacaine 0.2% provided no additional reduction in acute pain after THA when combined with a multimodal oral analgesic regimen consisting of acetaminophen, celecoxib, and gabapentin and is therefore not recommended. I ncreasing focus has been made on optimizing pain management after total hip arthroplasty (THA) as a prerequisite for early recovery and rehabilitation. Epidural analgesia and peripheral nerve blockade provide good pain control, 1Y3 but both techniques may have inherent risk of partial motor blockade, potentially delaying early postoperative mobilization.
Local infiltration analgesia (LIA) was introduced by Kerr and Kohan. 4 The technique covers a systematic intraoperative infiltration of a high-volume analgesic mixture (ropivacaine, ketorolac, and epinephrine) into the surgical wound along with subsequent postoperative injections through an intra-articular placed catheter. Although their study was a nonrandomized, noncontrolled, cohort study with several interventions included, because of the short length of stay, the simplicity, and the apparent safety, the LIA technique has gained widespread acceptance and is frequently used as part of a multimodal pain management strategy after THA.
Three randomized studies evaluating the effect of LIA in THA have been published, all reporting superior analgesia in the LIA group. 5Y7 However, some methodological inadequacies hinder sufficient interpretation, and consequently, the evidence for the analgesic effect of LIA in THA is questionable. 8 In particular, an LIA mixture combining ropivacaine and ketorolac applied in the previous studies (but without a nonsteroidal antiinflammatory drug [NSAID] for controls) makes the interpretation of the local anesthetic component and the LIA technique difficult. Thus, the analgesic benefit observed might be due to an analgesic effect of NSAID rather than an effect of the LIA per se. 8, 9 Therefore, the purpose of this randomized, double-blind, placebo-controlled trial was to clarify, whether intraoperative high-volume LIA with ropivacaine 0.2% combined with a simple multimodal oral analgesic regimen consisting of acetaminophen, celecoxib and gabapentin, would further reduce acute pain after primary, unilateral THA. The primary end point was pain during walking 8 hrs after surgery.
METHODS

Patients and Design
The trial was approved by the local research ethics committee (De Videnskabsetiske Komitéer for Region Hovedstaden, Hillerød, Denmark) and the Danish data protection agency and registered at www.clinicaltrails.gov (no. NCT00968955). Oral and written informed consent was obtained from all patients, and the study was carried out in accordance with the principles of the Helsinki Declarations. The CONSORT recommendations for reporting randomized controlled clinical trials was followed. , older than 18 years, and familiar with the Danish language were screened for inclusion in the study. Exclusion criteria were alcohol and medical abuse, daily use of strong opioids (morphine, fentanyl, hydromorphone, ketobemidone, methadone, nicomorphine, oxycodone, and pethidine) or glucocorticoids, body mass index (BMI) higher than 40 kg/m 2 , allergies to local anesthetics, pregnancy or breast-feeding, diabetic neuropathy, rheumatoid arthritis, and neurological or psychiatric diseases potentially influencing pain perception. The design was a 2-center, prospective, randomized, double-blind, placebo-controlled trial.
Randomization and Blinding
One hundred twenty patients were randomly assigned to 2 groups of 60. A random allocation sequence concealed in 120 consecutively numbered, opaque, sealed envelopes determining active treatment or placebo was computer-generated by a project nurse not otherwise involved in the trial. The envelopes were opened on the morning of surgery, and the trial drug was prepared by an anesthetist not otherwise involved with data collection. The envelopes were divided between the 2 hospitals, and no stratification was made. Trial participants, care providers, and data collectors were all blinded to the allocation throughout the study.
Study Parameters
The primary end point was pain during walking with a walking aid (5 m) 8 hrs after surgery. Secondary end points were pain at rest (supine), pain on 45 degrees of passive flexion of the hip with the leg straight, and cumulative consumption of oxycodone 8 hrs after surgery. Pain during walking was assessed 4 and 8 hrs postoperatively and pain at rest and on hip flexion 2, 4, 6, and 8 hrs postoperatively using the 100-mm visual analog scale (VAS) (0 mm indicating no pain and 100 mm indicating worst pain imaginable). The investigator asked the patients at each time point: ''Please show me how much pain you have right now on the VAS, where the lower limit indicates no pain and the upper limit indicates worst pain imaginable.'' Complications occurring during hospitalization were registered.
Study Intervention
Local infiltration analgesia was performed intraoperatively using ropivacaine 0.2% (AstraZeneca, Södertälje, Sweden) with epinephrine (10 Kg/mL) or saline 0.9% (placebo). A total volume of 150 mL was injected using a systematic technique ensuring uniform delivery to all tissues incised and instrumented during the surgery. 4 The first 50 mL was systematically injected in the periacetabular tissues after reaming of the acetabulum and before insertion of the acetabular component. After insertion of the femoral component, another 50 mL was injected in the cut rotators and the gluteus muscles and the proximal part of the iliotibial tract. Finally, 50 mL was systematically injected in the subcutaneous layers. The subcutaneous injections (in case of allocation to ropivacaine) were without epinephrine to minimize the risk of subcutaneous blister formation. 4 No intraarticular catheter was placed, and no postoperative injections were administered.
Anesthesia, Surgery, and Analgesia
Anesthesia, surgery, and analgesia were standardized for all patients. Thus, interventions were fixed for all but the modality under investigation. Surgery was performed under lumbar spinal anesthesia with 12.5 mg of isobaric bupivacaine (0.5%) and optional sedation with propofol (1Y5 mg/kg per hour) by 1 of 5 surgeons all specialized in arthroplasty and the LIA technique.
They agreed on a similar surgical and LIA technique before the study. Cefuroxime 1.5 g and tranexamic acid 1 g were administered intravenously. Intraoperative fluid therapy was standardized and consisted of saline 0.9% 5 mL/kg per hour and colloid (Voluven; Fresenius Kabi AB, Uppsala, Sweden) 7.5 mL/kg per hour. 11 Total hip arthroplasty was performed using a standard posterior approach without the use of minimally invasive surgical techniques. Drains were not used. Prostheses were Bimetric with Ringloc-cup or Magnum-cup (Biomet-Merck, Inc, Warsaw, Ind) or CLS Spotorno with Trilogy-cup (Zimmer, Inc, Warsaw, Ind).
A multimodal oral analgesic regimen consisting of slowrelease acetaminophen 2 g, celecoxib 400 mg, and gabapentin 600 mg was instituted 1 to 2 hrs preoperatively. Rescue analgesics (administered if VAS 950 at rest) consisted of sufentanil 5 Kg intravenously in the postanesthesia care unit (PACU) and subsequently, oral oxycodone 5 mg. Patients followed a welldefined, fast-track rehabilitation regimen and were discharged to their homes according to functional discharge criteria. 12 
Statistical Analyses
The estimated sample size for the primary effect variable was calculated based on the results from a pilot study (n = 10), where average pain during walking (5 m) 8 hrs after primary, unilateral THA was found to be 28 mm with an SD of 22 mm. A total sample of 120 patients would allow the detection or rejection of a 50% reduction in pain in the ropivacaine group compared with the placebo group at a 2-sided 5% significance level with a power of 90% and 15% dropouts.
Continuous numeric variables were assessed for normality of distribution (Kolmogorov-Smirnov). Depending on whether variables were normally distributed (only the case for age, BMI, and duration of surgery), they are presented as mean with range, and otherwise as median with interquartile range (IQR). Categorical variables are presented as count with percentage, and tests for significant differences between groups were done with the W 2 test. The Mann-Whitney rank sum test was used for comparison between groups because pain data were not normally distributed and no meaningful transformation could be performed (many values = 0 and skew was very positive). 13 Subsequent Bonferroni adjustment for repeated measurements was applied. In addition, summarized (cumulated) pain was calculated for each of the 3 pain assessments by adding up pain scores from the different time points (2Y8 hrs). Data analyses were conducted using SPSS for windows, version 12.0 (SPSS, Inc, Chicago, Ill). P G 0.05 was considered statistically significant.
RESULTS
One hundred twenty patients were included, and all received their allocated intervention (Fig. 1) . Baseline demographic and perioperative characteristics of study patients are shown in Table 1 . Groups were comparable. Pain hindering walking (5 m) was not different to a significant degree between the 2 groups (count [%], ropivacaine vs placebo: 7 patients [0.12] vs 2 patients [0.03], P = 0.08) (Fig. 1) . For secondary end points (pain at rest and pain on passive hip flexion), data were only missing once (1 patient in the ropivacaine group was asleep 8 hrs postoperatively).
For the first 8 hrs after surgery, pain was low for all pain assessments (pain during walking, pain at rest, and pain on passive hip flexion) at all time points investigated, and no significant difference between the ropivacaine and placebo groups was seen (Fig. 2) . No significant difference in summarized pain (added pain scores) for each of the 3 pain assessments (walking P = 0.11, rest P = 0.84, passive hip flexion P = 0.52) was One patient in the placebo group developed computed tomographic scan verified cerebral infarction after surgery. A patient in the ropivacaine group had quadriceps muscle palsy, and electromyography suggested that the complication was due to an intraoperative local mechanical injury on the femoral nerve rather than related to the ropivacaine infiltration because the nerve injury was limited to the branches innervating the quadriceps muscle.
A post hoc power analysis yields a power of 93% for the primary end point, pain during walking 8 hrs after surgery (mean [SD] , ropivacaine vs placebo: 28 [23] vs 26 [21] ).
DISCUSSION
This randomized, double-blind, placebo-controlled trial demonstrated that intraoperative high-volume LIA with ropivacaine 0.2% provided no additional reduction in acute pain after 
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THA when combined with a multimodal oral analgesic regimen. Furthermore, no significant reduction in consumption of rescue oxycodone was achieved.
Our findings are in contrast to previous results from randomized trials in the orthopedic literature, all reporting superior analgesia in the LIA group. 5Y7 Reduced pain (20Y96 hrs postoperatively) and opioid requirement (96 hrs postoperatively) were reported when intraoperative and postoperative LIA was compared with continuous epidural analgesia. 5 When intraoperative and postoperative LIA was compared with saline infiltration, a reduction in pain (up to 2 weeks postoperatively) and opioid requirement (96 hrs postoperatively) was reported. 6 Finally, reduced pain (in PACU) and opioid requirement (24 hrs postoperatively) were reported when intraoperative LIA was compared with no infiltration. 7 However, some methodological problems hinder the exact interpretation of these trials. First, NSAID was not administered in the control group in any of the 3 trials, 5Y7 making the interpretation of the local anesthetic component and the LIA technique in particular difficult 8 ; second, 1 trial was not blinded, and pain not sufficiently assessed/ reported 5 ; third, 1 trial was not placebo-controlled, and the surgeon was not blinded 7 ; and fourth, in 2 trials, administration of morphine in LIA versus control groups was unmatched. 5, 7 Because an intraoperative catheter was not applied, we did not evaluate the effect of repeated postoperative LIA injections. The role of catheter administration and its placement and type is unknown, and we consider in keeping with results from a recently published trial 14 that a significant analgesic effect of postoperative injections is unlikely, when it is not observed with the systematic intraoperative infiltration. In contrast to previous trials, we omitted ketorolac from the LIA-mixture because celecoxib was included in the comprehensive multimodal oral analgesic regimen. The analgesic benefit of LIA previously reported in THA 5Y7 might be due to an analgesic effect of NSAID in combination with a less comprehensive multimodal oral analgesia. This assumption is based on the results from the present study in combination with previous results indicating that NSAID provides analgesia whether administered locally or systemically and probably without important difference. 9 Our study might be limited by pain scores a little less than 30 mm in both groups, which challenge the demonstration of an intervention effect. 15, 16 However, because LIA is already widely used in THA, our aim was to clarify if LIA in addition to a simple multimodal oral analgesic regimen would reduce acute postoperative pain additionally. Furthermore, the large sample size made the trial sufficiently powered ensuring final evaluation. At the same time, our study does not exclude that intraoperative LIA may have a minor, short-lasting analgesic effect with a less comprehensive oral analgesic regimen or in selected patients (high pain responders).
It may also be argued that the absent effect of LIA may be explained by a continuous effect of the spinal anesthesia. However, a small dose of bupivacaine was used, which should not have prolonged analgesic effects. 17 The results from the present study illustrate that a simple multimodal oral analgesic regimen with acetaminophen, celecoxib, and gabapentin provides sufficient analgesia with acceptable low opioid requirements in opioid naive patients after THA, and it emphasizes the need for procedure-specific trials because LIA might be effective in other procedures. 8 In our opinion, the applied multimodal oral analgesic regimen seems effective, simple, and easy and may be preferable compared with more invasive techniques. However, further data are required on the specific role of gabapentin regarding efficacy and adverse effects, especially the concerns about sedation in older patients 18, 19 (we did not measure sedation level). Although acceptable immediate postoperative pain relief after THA was achieved in opioid-naive patients with a simple multimodal oral nonopioid analgesic regimen in this study, higher pain scores have been reported by other investigators. 1, 20 This difference may relate to study design (basic analgesic regimen and duration of follow-up) or surgical technique. Therefore, further studies in subacute and late postoperative recovery and rehabilitation are needed. 21 In this context, it remains noteworthy that not only pain but also multiple factors may limit ambulation ability and other functional recovery parameters. 1 In future pain trials, the effects of long-duration administration of simple oral analgesics on long-term outcome need to be studied. Moreover, continuous low-dose peripheral nerve blockade 1, 22, 23 and systemic administration of high-dose glucocorticoids 24, 25 may play important roles because they may be provided on an ambulatory basis, thereby possibly prolonging their benefits. However, potential risks of motor adverse effects resulting in delayed mobilization or falls 26 and risk of deep infection, 25 respectively, need to be clarified. Finally, these modalities need to be evaluated against the efficacy, safety, and costs of other evidence-based components of multimodal analgesia. 3 In conclusion, intraoperative high-volume LIA with ropivacaine 0.2% provided no additional reduction in acute pain after THA when combined with a multimodal oral analgesic regimen consisting of acetaminophen, celecoxib, and gabapentin. Acceptable acute postoperative pain relief was achieved with the oral analgesic regimen, and LIA is not recommended in THA.
